Genenta Science SPA (GNTA) News

Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider

MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a...

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors

MILAN, Italy and NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Genenta to Present at Upcoming Scientific and Investor Conferences

MILAN, Italy and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ: GNTA) a...

Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments

Company Selects Refractory Advanced Genitourinary Malignancies including Renal Cell Cancer as Second Indication...

The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma

MILAN, Italy and NEW YORK, June 29, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage...

Notice of Effectiveness (effect)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NOTICE OF EFFECTIVENESSEffective Date:May 24, 2023 4:30...

Genenta to Provide Update on Lead Product Temferon™

MILAN, Italy and NEW YORK, May 16, 2023 (GLOBE NEWSWIRE) -- Luigi Naldini, Ph.D., M.D., co-founder and...

Securities Registration (foreign Private Issuer) (f-3)

  As filed with the Securities and Exchange Commission on May 12, 2023   Registration No. 333-    ...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

      UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549      ...

Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing

Funds available expected to be sufficient for Genenta to continue to operate into the first quarter of 2025Net...

Annual and Transition Report (foreign Private Issuer) (20-f)

0001838716 false FY

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

      UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 6-K &n...

Amended Statement of Ownership (sc 13g/a)

      UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE...